Larvol Delta - Apros-Therapeutics-to-Present-Interim-Clinical-Data-from-a-Phase-1-Study-Evaluating-APR003-at-the-2022-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting-and-World-Vaccine-amp-Immunotherapy-Congress-WVIC-West-Coast

APR003 - Apros Therap

https://www.businesswire.com/news/home/20221106005001/en/Apros-Therapeutics-to-Present-Interim-Clinical-Data-from-a-Phase-1-Study-Evaluating-APR003-at-the-2022-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting-and-World-Vaccine-Immunotherapy-Congress-WVIC-West-Coast

Nov 7, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next